Abstract: An encapsulation device includes: a fluid injection device that injects a first liquid forming a core; a liquid film holder that holds in film form a second liquid forming a shell containing the core; and a liquid contact device that makes the shell in contact with a third liquid, in which the first liquid is injected toward a liquid film of the second liquid retained by the liquid film holder to form a core, the core is wrapped with the second liquid on passing through the liquid film of the second liquid, thereby forming the shell, and the shell is made in contact with the third liquid to induce chemical reaction.

Abstract: There is provided an aseptic combination preparation to be mixed at the time of use, characterized in that the same medicinal ingredients are divided and preserved in two or more chambers. The aseptic combination preparations according to the present invention are a mixing type at the time of their use and are useful as infusions, various dialysis fluids, intraocular perfusion/washing solutions, coronary perfusion solutions, myocardial protective solutions, peritoneal lavage solutions, solutions for organ preservations, etc., which can eliminate adverse effects caused by medical error on a living body.

Abstract: The present invention pertains to therapeutic compositions and delivery systems comprising at least one microparticle or nanoparticle. In various embodiments, the surface of the microparticle or nanoparticle is modified or functionalized with at least a portion of an isolated cellular membrane, such as an isolated plasma membrane. In addition, the microparticle or nanoparticle contains at least one active agent, such as a therapeutic and/or imaging agent. In additional embodiments, the compositions and delivery systems of the present invention may be used for targeted delivery of an active agent. Also provided are methods of making the therapeutic compositions and delivery systems of the present invention.

Abstract: Particles having a core based on at least one biodegradable organosoluble polymer. At least a part of the surface of the particles is coated with at least one hyaluronan or a derivative thereof, the hyaluronan being a water-soluble, amphiphilic hyaluronan of which the carboxylic functions are in part transformed to form hydrophobic groups.

Abstract: The disclosure relates to substantially uniform, high density microspheres and methods of making the microspheres. The microspheres can be made to be small in size with a narrow range of particle size distribution and a high sphericity. In one aspect, the microspheres provided herein are provided in the form of spherical cores comprising maltodextrin or maltodextrin and starch and are prepared using a centrifugal tumbling-granulating-coating apparatus. In another aspect, the spherical cores can be powder-coated with one or more layers of small particles, such as starch particles. The microspheres provided herein can be used as cores for multi-particulate solid dosage delivery systems as well as other pharmaceutical, nutraceutical, food, personal care, and other applications.

Abstract: Drug delivery to the pulmonary system has been achieved by encapsulation of the drug to be delivered in microparticles having a size range between 0.5 and ten microns, preferably in the range of two to five microns, formed of a material releasing drug at a pH of greater than 6.4. In a preferred embodiment, the drug delivery system is based on the formation of diketopiperazine microparticles which are stable at a pH of 6.4 or less and unstable at pH of greater than 6.4, or which are stable at both acidic and basic pH, but which are unstable at pH between about 6.4 and 8. Other types of materials can also be used, including biodegradable natural and synthetic polymers, such as proteins, polymers of mixed amino acids (proteinoids), alginate, and poly(hydroxy acids). In another embodiment, the microparticles have been modified to effect targeting to specific cell types and to effect release only after reaching the targeted cells.

Abstract: Methods and compositions for delivering agents (e.g., gene silencing agents) and molecules to cells using yeast cell wall particles are presented herein. Embodiments of the invention are particularly useful for the delivery of nucleic acids (e.g., siRNAs) to cells.

Abstract: Compositions which deliver adsorbents, alone or in combination with active drug “degrading molecules,” in a site-specific manner to the intestine, and which eliminate or at least lower the concentration of residual unwanted material within the intestine, and methods of treatment using the compositions, are disclosed. The compositions are ideally designed to specifically release the adsorbents in a programmed manner at a specific site of the intestinal tract. Programmed delivery prevents adsorbents from interfering with the normal absorption process of a given molecule after oral absorption, until it reaches the lower part of the small intestine. The compositions can be used to adsorb, and therefore remove, any residual drug, metabolite thereof, or bacterial toxin after oral or parenteral administration which would otherwise cause adverse effects in the lower intestine and/or colon.

Abstract: The invention provides injectable, stem cell-containing calcium phosphate bone pastes for bone tissue engineering and methods of making and using the same.

Abstract: A chewing gum carrier system for supplemental nutrients and pharmaceutical products is provided using compressed gum with a buffering system designed for simultaneous release and ultimate exhaustion of both flavor elements and supplementary nutritive elements and/or pharmacological values by use of a sodium carbonate, bicarbonate and magnesium oxide buffering system included in a compressed gum base, preferably using a plasticizer to prevent premature crumbling of the compressed gum base.

Abstract: A method for stabilizing conjugates between macromolecule and nanoparticle by forming a thin reinforcement layer over the surface of a nanoparticle after macromolecule chains have attached to the surface of the nanoparticle. The stabilized conjugates can be used in a wide range of applications such as in vitro diagnostics, in vivo imaging and therapeutics, which need to be conducted under various severe or harsh conditions.

Abstract: A method of delivering a therapeutic agent by providing a cross-linked polymer encapsulating the therapeutic agent to a site in a patient. The degradation rate of the cross-linked polymer is correlated with a local concentration of an indicator, and the therapeutic agent is released as the cross-linked polymer degrades.

Abstract: Process for extracting hydrophobin from a solution wherein carrageenan is added to the solution and the pH of the solution is brought below 3.5, and the ionic strength of the solution is below 0.5.

Abstract: The present invention provides methods and compositions to selectively and directly deliver nanoparticles carrying an active agent to tumor cells. The active agent is internalized by the tumor cells, producing an anti-tumor effect for therapeutic applications and/or depositing a detectable marker for diagnostic applications. The present invention further provides a p53 chimera that circumvents the dominant negative activity of mutant p53 as a therapeutic in the treatment of cancer and reduction of mor size.

Abstract: Nanocomposite particles having good solubility and redispersibility in water are provided. The nanocomposite particles include a sugar material and nanoparticles containing a drug to be delivered and a biodegradable polymer, the sugar material being disaccharide, and a mass ratio of the nanoparticles to the disaccharide being within the range of from 40:60 to 60:40.

Abstract: The present invention relates to newly identified genes that encode proteins that are involved in the synthesis of L-ascorbic acid (hereinafter also referred to as Vitamin C). The invention also features polynucleotides comprising the full-length polynucleotide sequences of the novel genes and fragments thereof, the novel polypeptides encoded by the polynucleotides and fragments thereof, as well as their functional equivalents. The present invention also relates to the use of said polynucleotides and polypeptides as biotechnological tools in the production of Vitamin C from microorganisms, whereby a modification of said polynucleotides and/or encoded polypeptides has a direct or indirect impact on yield, production, and/or efficiency of production of the fermentation product in said microorganism. Also included are methods/processes of using the polynucleotides and modified polynucleotide sequences to transform host microorganisms.

Abstract: Swellable particles for delivery of a drug or other working agent to the pulmonary system are provided. The swellable particles include a dehydrated (dry) aerodynamic particle diameter of 5 ?m or less to enable delivery to the respiratory tract, such as for example to the tracheo-bronchial airways of the upper respiratory tract and/or to the alveolic regions of the deep lung, and a hydrated particle diameter that is greater than 6 ?m volume mean diameter to retard or prevent their phagocytosis by the macrophages present in airways of the respiratory tract.

Abstract: The invention refers to an oral solid pharmaceutical composition comprising a mixture of: (a) pellets comprising lansoprazole or a pharmaceutically acceptable salt thereof being free of alkaline-reacting compounds and (b) pellets comprising lansoprazole or a pharmaceutically acceptable salt thereof together with alkaline-reacting compounds.

Abstract: Pharmaceutical compositions of topiramate for once-a-day oral administration are provided. The formulations comprise a sustained-release component and an optional immediate-release component, the compositions of which can be selectively adjusted, respectively, to release the active ingredient along a pre-determined release profile. Method of treating or preventing pathological disorders in mammalian subjects comprising the administration of the novel formulations disclosed herein is also provided.

Abstract: Described are injectable formulations of particulate olanzapine that produce a prolonged duration of action upon administration, and methods of making and using such formulations. The injectable formulations comprise particulate olanzapine.

Abstract: Acid-containing oral pharmaceutical compositions are provided wherein the pharmaceutical active agents are peptide compounds (i.e., those that include a plurality of amino acids and at least one peptide bond in their molecular structures). Certain barrier layers and/or particulate coated acid are used to reduce any adverse interactions that might otherwise occur between the acid of the compositions and other components of the composition. Use of these barrier layers and/or use of particulate coated acid is believed to promote a more simultaneous release of the components of the composition than is achieved by prior art acid-protection techniques, thus enhancing, and making more consistent, the bioavailability of the active peptide compounds.

Abstract: A method is provided for producing a sugar-coated preparation including a solid composition containing a pharmacologically active ingredient and a sugar coating layer. The method comprises a step of forming the sugar coating layer with a sugar coating composition containing one or more sugar-alcohols selected from the group consisting of mannitol and erythritol and a polyvinyl alcohol-based resin. The sugar-coated preparation includes a solid composition containing a pharmacologically active ingredient and a sugar coating layer, wherein the sugar coating layer is made of a sugar coating composition containing one or more sugar-alcohols selected from the group consisting of mannitol and erythritol and a polyvinyl alcohol-based resin.

Abstract: The present disclosure describes a delivery device for administration of nutraceuticals or pharmaceuticals, which device contains a soft gel shell comprising a gelatin-based water soluble film forming polymer, an acid insoluble polymer, and at least one reducing sugar and water, including processes, gel mixtures used for device production, and coatings containing such gel mixtures.

Abstract: There is provided a method for suppressing a pro-inflammatory immune response in a cell, comprising providing to a cell sialic acid or analogs thereof, wherein the sialic acid or analogs are presented by a substrate such that a pro-inflammatory immune response in a cell is suppressed or an anti-inflammatory immune response is increased in a cell. Further, there is provided a method of treatment of inflammatory disease in a subject in need thereof. There is also provided a drug delivery device and a biomaterial which can modulate the inflammatory response in a subject.

Abstract: A method for preparing polysaccharide nanocomposite particles is provided. The method comprises providing a first solution comprising an active component and a polysaccharide; adding a cross-linking agent to the first solution to provide a second solution; and allowing the second solution to conduct the reaction to form polysaccharide nanocomposite particles. The polysaccharide nanocomposite particles thus prepared show good coating ratio and enhanced applicability. Also provided is a method for inducing cancer cell apoptosis in a subject, comprising administrating to the subject an effective amount of the polysaccharide nanocomposite particles.

Abstract: A process for producing an oral preparation containing a first water-swellable gel-forming layer and a second water-swellable gel-forming layer as outermost layers, a medicine being sealed in an inner space formed by bonding the periphery of the first water-swellable gel-forming layer and the periphery of the second water-swellable gel-forming layer either directly or via an adhesive layer, the process including (a) a step of forming a first water-swellable gel-forming layer, (b) a step of forming a recess in a predetermined area of the first water-swellable gel-forming layer, (c) a step of filling the recess with a medicine to obtain a medicine-containing body, and (d) a step of forming a second water-swellable gel-forming layer over the medicine-containing body directly or via an adhesive layer so that the first water-swellable gel-forming layer and the second water-swellable gel-forming layer are bonded around the recess, and a process for continuously producing the oral preparation are disclosed.

Abstract: An embodiment in accordance with the present invention provides a thermo-chemoembolization formulation and method for enhanced interventional image-guided therapy for cancer. The T-C formulation includes magnetic iron oxide nano-particles (MIONs) that heat when exposed to an alternating magnetic field (AMF), a liquid tumorphilic drug carrier that enhances tumor retention of the T-C formulation, and a chemotherapeutic or radiotherapeutic agent. The T-C formulation enhances delivery of heat and chemo- or radio-therapeutic agents with hyperthermia produced by magnetic nanoparticles to improve therapeutic outcomes. The magnetic nanoparticles and tumorphilic drug carrier also allow for multimodal image-guided monitoring of treatment and patient follow-up. The method for enhanced interventional image-guided therapy for cancer includes using an AMF to heat the T-C formulation and activate the thermotherapy.

Abstract: The present application refers to cells, e.g. mesenchymal stem cells or mesenchymal stromal cells, or any further suitable cell, encoding and secreting a neuroprotective factor, an anti-angiogenic factor and/or any other protein or protein-like substance suitable for (intraocular) treatment of eye diseases. Such eye diseases include glaucoma and other optic nerve disorders, retinal diseases, particularly retinitis pigmentosa (RP), age-related macular degeneration (AMD) and diabetic retinopathy, etc. The cells used herein are encapsulated in a (spherical) microcapsule, preferably comprising a core and at least one surface layer, to prevent a response of the immune system of the patient to be treated. The present application also refers to the use of these (spherical) microcapsule(s) or such factors for (intraocular) treatment of eye diseases as defined herein (for the preparation of a (pharmaceutical) composition) for the treatment of such eye diseases.

Abstract: A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material.

Abstract: In one aspect, the present invention features a method of administering an active ingredient, said method comprising chewing an oral dosage form comprising a texture masked particle, said texture masked particle comprising a) a core containing an active ingredient; b) a first coating layer comprised of a taste masking agent that substantially covers the core, wherein said taste masking agent is comprised of an insoluble film forming polymer and a non-enteric, water soluble polymer; and c) a second coating layer on the surface of the first coating layer.

Abstract: This invention provides methods and compositions to preserve bioactive materials in a matrix of powder particles. Methods provide high-pressure gas spraying and/or near supercritical spraying of formulations followed by drying in a stream of conditioned gas to form stable powder particles containing bioactive materials.

Abstract: The present invention relates to a method of treating or preventing pain or pains induced by an anti-neoplastic agent, comprising the step of administering an effective amount of at least one botulinum neurotoxin to a patient in need thereof.

Abstract: The present invention provides nanoparticles including a metallic core having a length along each axis of from 1 to 100 nanometers and a coating disposed on at least part of the surface of the metallic core, wherein the coating comprises polydopamine, along with methods for making and using such nanoparticles. The metallic core may be gold, silver or iron oxide and the polydopamine coating may have other substances bound to it, such as silver, targeting ligands or antibodies, or other therapeutic or imaging contrast agents. The disclosed nanoparticles can be targeted to cells for treating cancer or bacterial infections, and for use in diagnostic imaging.

Abstract: The present invention relates to a galenic form comprising particles capable of specifically adsorbing the undesirable molecules present in the digestive tract, to the method for preparing same and to the use thereof in particular for producing a medicine intended for preventing or treating undesirable effects linked to an imbalance of the intestinal and/or colonic flora that can result for example from treatment with antibiotics.

Abstract: This disclosure relates to a sustained-release oral dosage form for once-a-day administration comprising a matrix containing a viscosity modifier and coated granules containing hydromorphone. The dosage form can have a release profile such that 16 hours following administration, less than about 85 percent of the hydromorphone is released. In addition, the dosage form may have alcohol and/or crush resistance.

Abstract: Disclosed are a solid state synthesis method of silver nanoparticles, and silver nanoparticles synthesized thereby. The method includes mixing a silver salt and a water soluble polymer acting as both a reducing agent and a protecting agent to produce a solid mixture, and milling the solid mixture by a high-speed vibration milling process to form silver nanoparticles within the water soluble polymer. According to the present invention, silver nanoparticles can be easily and simply produced in a solid state through high speed vibration milling, thereby reducing costs for industrial production and transportation of silver nanoparticles. In addition, the synthesized silver nanoparticles can be used for a long time since the silver nanoparticles are stable in a solid state for 1 year or more.

Abstract: Encapsulation compositions in which an encapsulate (A) is encapsulated in a matrix (B) may be prepared by: (i) mixing matrix (B) with a liquid plasticizer and encapsulate (A) in an extruder, to obtain a melted mixture of encapsulate (A) and matrix (B); and (ii) extruding the melted mixture, to obtain an extruded mixture.

Abstract: The invention provides compositions for controlled delivery and/or containment of therapeutic and/or diagnostic agents comprising the agent or agents encapsulated by a matrix containing chitosan, polyethylene glycol (PEG) and/or polyvinyl alcohol (PVA), and tetra-methoxy-ortho-silicate (TMOS) or tetra-ethoxy-ortho-silicate (TEOS), as well as methods for preparing the compositions, and uses of the compositions for therapy and imaging.

Abstract: A manufacture method of microcapsule, comprises a step of extraction, by extracting active substance from a sample of Chinese angelica and obtaining an extract; a step of encapsulation, by encapsulating the extract with a covering, wherein the extract and the covering are mixed and co-dropped in a solidified solution for solidifying the covering, and the extract is encapsulated in the solidified covering to obtain a microcapsule; and a step of drying, by drying and finalizing the microcapsule.

Abstract: Enteric coated multiparticulate formulations that use L-menthol as an active ingredient are disclosed. In one embodiment, the multiparticulate formulation comprises a plurality of particulates having a reduced release under gastric conditions and an elevated release at neutral pH. The particulates comprise a core comprising L-menthol as an active ingredient. The L-menthol is supplied to the core as an at least 80% pure L-menthol material. An enteric coating is over the core. The enteric coating is effective to release at least about 80% of the L-menthol within about two hours of being placed in a substantially neutral pH environment. Other aspects of the invention include methods of making and methods of using the multiparticulate formulations.

Abstract: A floating granule having a solid core, on which an active ingredient is supported, and a compound capable of generating a gas discharge which is constituted by an alkaline agent, characterised in that it does not comprise an acid agent that is capable of generating a gas discharge.

Abstract: Sunscreen compositions containing a discontinuous oil phase dispersed in a continuous water phase, at least 10% by weight of an organic UV-filter, a water-insoluble, C2-C8, liquid silicone, a branched fatty acid ester of a polyprotic carboxylic acid; and at least 2% by weight of a mineral particulate having a starch coating applied to the surface thereof.

Abstract: A chitosan composition which forms a hydrogel at near physiological pH and 37° C., comprising at least one type of chitosan having a degree of acetylation in the range of from about 30% to about 60%, and at least one type of chitosan having a degree of deacetylation of at least about 70% is disclosed. Further disclosed is a chitosan composition which forms a hydrogel at near physiological pH and 37° C., comprising at least one type of chitosan having a degree of deacetylation of at least about 70% and a molecular weight of from 10-4000 kDa, and at least one type of a chitosan having a molecular weight of from 200-20000 Da. Further disclosed are methods of preparation and uses of the chitosan compositions.

Abstract: Described herein are methods of cryopreserving cells that have been suspended in alginate as well as methods for encapsulating cryopreserved cells that have been suspended in alginate. Further provided herein are cellular compositions comprising cells that have been processed in accordance with the methods described herein.

Abstract: The present invention relates to a pulsatile-release pharmaceutical formulation of dexlansoprazole composed of a single type of enteric coated pellets and the process for the preparation thereof.

Abstract: The invention provides a composition comprising microparticles of a water-insoluble or poorly soluble compound, at least one phospholipid, and at least one surfactant, produced by applying an energy to a mixture comprising particles of the compound, the at least one phospholipid, and the at least one surfactant so as to obtain the microparticles. The invention also provides a process for preparing microparticles of a water-insoluble or poorly soluble compound. The process includes mixing particles of a water-insoluble or poorly soluble compound with at least one phospholipid and at least surfactant to form a mixture and applying energy to the mixture sufficient to produce microparticles of the compound. The methods of the invention allow for the production of microparticles smaller than particles produced through previously known methods and the microparticles exhibit advantageous properties including remarkable resistance to particle size growth during storage.

Abstract: A drug in a solubility-improved form is combined with a concentration-enhancing polymer in a sufficient amount so that the combination provides substantially enhanced drug concentration in a use environment relative to a control comprising the same amount of the same solubility-improved form of drug without the concentration-enhancing polymer.

Abstract: We have disclosed an implantable sustained release composition comprising, a biocompatible, biodegradable polymer, a cyclodextrin inclusion complex of a poorly water soluble pharmaceutical agent present, and a plasticizer, where the polymer is the minority phase of the formulation. Furthermore, The we disclose an implantable sustained release composition that provides a detectable plasma level of an otherwise poorly soluble drug for at least 28 days.

Abstract: Disclosed herein is a controlled release particle comprising a therapeutically effective amount of acid fibroblast growth factor (aFGF), entrapped by a particle composed by a biocompatible anionic biopolymer capable of binding to aFGF, and a cationic polymer. The method for manufacturing the controlled release particle and the method of using the particle for treating nervous injury are also provided.

Abstract: The invention concerns an oral galenic form for prolonged release of anti-hyperglycaemic (metformin) active principles. Said medicine enables to obtain an efficient therapeutic protection over 24 hours by overcoming the problems of bypass of the absorption window and the massive localised release of active principles. Therefor, said medicine comprises several thousand anti-hyperglycaemic (metformin) microcapsules each consisting of a core comprising at least an anti-hyperglycaemic agent and of a coating film applied on the core and enabling the prolonged release in vivo of the anti-hyperglycaemic agent. Said microcapsules have a grain size distribution ranging between 50 and 100 microns. The reproducibility of the transit kinetics and hence of bioavailability are very high. There results for the patient a lesser risk of hyperglycaemic or hypoglycaemic. The invention also concerns the preparation of said medicine and the use of a plurality of said microcapsules for making an anti-hyperglycaemic medicine.